紫杉醇联合卡铂或奥沙利铂治疗复发上皮性卵巢癌  

Paclitaxel Combined With Carboplatin or Oxaliplatin in Treatment of Recurrent Epithelial Ovarian Cancer

作　　者：曹磊 朱林 张梅玲[2] 刘平[2] 

机构地区：[1]江苏省宿迁市第一人民医院肿瘤中心,江苏宿迁223800 [2]江苏省人民医院肿瘤内科,江苏南京210029

出　　处：《中国继续医学教育》2016年第30期122-124,共3页China Continuing Medical Education

摘　　要：目的评估紫杉醇联合卡铂或奥沙利铂治疗复发上皮性卵巢癌的疗效及安全性。方法选取2010年1月~2014年6月108例患者,回顾性分析紫杉醇联合卡铂或奥沙利铂治疗复发性上皮性卵巢癌,研究客观缓解率及毒副反应。结果研究组和对照组ORR分别为63.16%、29.41%（P〈0.05）,DCR分别为89.47%、84.31%（P〉0.05）;研究组不良反应多为骨髓抑制,对照组周围神经毒性更为常见。结论紫杉醇联合卡铂或奥沙利铂均可用于复发上皮性卵巢癌,毒副反应尚可耐受。Objective To observe the efficacy and safety of paclitaxel plus carboplatin or oxaliplatin for recurrent epithelial ovarian cancer. Methods 108 patients from January 2010 to June 2014 were chsoen, a retrospective analysis of paclitaxel combined with carboplatin or oxaliplatin in the treatment of recurrent epithelial ovarian cancer, study objective response rate and toxicity. Results The ORR of study group and control group were 63.16%, 29.41%（P〉0.05）, DCR were 89.47%, 84.31%（P〈0.05）. The adverse reactions in the study group were mostly bone marrow suppression, and peripheral nerve toxicity was more common in the control group. Conclusion The efficacy and safety of paclitaxel plus carboplatin oroxaliplatin in treatment of recurrent epithelial ovarian cancer is considered similar.

关 键 词：紫杉醇 卡铂 奥沙利铂 上皮性卵巢癌 客观缓解率 

分 类 号：R737[医药卫生—肿瘤]